Featured news

[2022.10.03] Eligo Bioscience secures additional landmark CRISPR patent

[2022.10.03] Eligo demonstrates for the first time that in situ base editing of the microbiome can be achieved with high efficiency

The presence or absence of a single bacterial gene can trigger or aggravate a variety of diseasesI


 This genetic causality is being demonstrated in a growing number of therapeutic areas 



Introducing our GEM (Gene Editing of the Microbiome) platform

A first-in-class proprietary platform to edit the microbiome gene repertoire in vivo

We are hiring!

Join Our Team

Our Partners & Investors